gsk medical affairs jobs near london

Oncoimmunology. and physicians? 8. 2. [Poster No. ORAL FEATURED POSTER: Efficacy of Niraparib by Timing of Surgery and Residual Disease: A Post-Hoc Analysis of Patients in the PRIMA/ENGOT-OV26/GOG-3012 Study, 5. [Oral presentation available here; Abstract A6247]. Cookies will only be set if you choose to accept them. [Poster No. 2. JASPER: Efficacy and Safety of First-Line (1L) Niraparib Plus a Programmed Death Receptor-1 Inhibitor (PD-1i) in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC), 6. 4. Gsk Medical jobs in London Sort by: relevance - date Page 1 of 116 jobs new Medical Scientific Liaison - Specialty/Rheumatology Team Bui. Outcomes Following Continuation or Stopping Long-Term Mepolizumab Treatment in Patients With Severe Eosinophilic Asthma: The Randomized COMET Trial. Sci Transl Med. A Phase 2, Single Arm, Open Label Study to evaluate the safety and efficacy of niraparib combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer following frontline platinum-based chemotherapy with bevacizumab (OVARIO), 5. The PLUTO study: intravenous belimumab in children with systemic lupus erythematosus, 3. GSK3377794 is being investigated as a monotherapy and in combination with pembrolizumab in NY-ESO-1? A Randomized, Cross-Over Study Comparing Critical and Overall Errors, Teaching Time, and Preference of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers in Patients with Asthma. P1091; Abstract A3326]. GSK Solid Tumor Oncology Account Manager; Long Island East, NY Long Island-Queens 30d+ $160K-$216K Per Year (Employer est.) Describing asthma control and adherence in patients with extended Salford Lung Study (Ex-SLS) prescribed inhaled corticosteroids/long-acting beta agonists (ICS/LABAs). Zhang S, White J, Meeraus W, et al. Rates of Major Events in Untreated Patients Diagnosed ?With Anemia of CKD in France?? Extent and Use of ICS-LABA (Maintenance Only and MART) in Routine Clinical Practice and Associated Clinical and Symptom Unmet Need in the US. Apprentice programmes Kickstart a brilliant career with hands-on experience from day one. The most rewarding part about working at GSK is that I know I can count on my team and leadership for guidance and support. The estimated base pay is $154,315 per year. If you continue to see this This resource may include information that has not been approved by the US Food and Drug Administration. This information does not take the place of talking with your doctor. [Poster No. The information you are about to be referred to may not comply with the local regulatory requirements. ABSTRACT ONLY: Correlation of durability of response with best response or early discontinuation: A post hoc analysis of the GARNET endometrial cancer cohorts, 1. 1. POSTER: First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort, 2. [Poster No. 11. Findings From the Macunama Study, 5. 11. 61), 1. POSTER: A report of the postmarketing spontaneous safety data over 24 years for GSK?s measles-mumps-rubella (MMR) vaccine. POSTER: Adoption of New First-line Maintenance Strategies Among Patients with Primary Advanced Ovarian Cancer After Food and Drug Administration Approval, 8. pour nous faire part du problme. P792; Abstract A5630]. Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Improves Lung Function and Symptoms Compared With Tiotropium Monotherapy in Patients With Symptomatic Chronic Obstructive Pulmonary Disease at Risk of Exacerbations. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles, 4. 4. Moretz C, Hahn B, White J, et al. Real-World Insights on the Burden of Hypereosinophilic ?Syndrome (HES)?. 1. Medication adherence and COPD-related costs among patients with COPD treated with umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO). How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? Cancer Immunol Immunother. 6. Gibbons D, Marijam A, Symons JM, et al. The Severe Asthma Patient Experience: In-Clinic and Self-Administration of Mepolizumab. [Poster No. GSK. Patient Profiles in Eosinophilic Granulomatosis With Polyangiitis (EGPA) ? 2018;9:1-15. doi:10.3389/fi mmu.2018.01821. ein Mensch und keine Maschine sind. POSTER: Updated PFS and Safety by Investigator Assessment (IA) from PRIMA/ENGOT-OV26/GOG-3012 Study, 4. GlaxoSmithKline. J Clin Oncol. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. Bromodomain and extraterminal (BET) proteins bind to acetylated lysines in histone tails and other nuclear proteins to regulate the epigenetic landscape. Effect of Serostatus on the Efficacy of Sotrovimab in Preventing COVID-19 Progression, 2. POSTER: Immune-related endpoints in patients with advanced or recurrent endometrial cancer treated with dostarlimab in the GARNET study (IGCS ENCORE), 12. 178 Medical Affairs Jobs in London, England, United Kingdom (9 new) Regulatory Affairs Officer / RAQA Officer Hays Uxbridge, England, United Kingdom Be an early applicant 4 weeks ago. 4. Further information relevant to the local environment is available from the company or via the Product Information. Impact of the COVID-19 Pandemic on Health Care Resource Utilization (HCRU) and Costs in Asthma in the United States: A Population-Based Study. Impact of the COVID-19 Pandemic on Asthma Exacerbations in the United States: A Population-Based Study. PUBLICATION ONLY: Comparison of survival outcomes between dostarlimab and comparator treatments in patients with advanced/recurrent endometrial cancer in England: matching-adjusted indirect comparisons, 16. GSK's Dr. Len Friedland, VP and Director of Scientific Affairs and Public Health for Sideline RSV Behind the science Oncology Gaining a deeper understanding of myelofibrosis - a rare blood cancer. Effects of Daprodustat on Hemoglobin and Quality of Life in Patients With CKD: Results of the ASCEND-NHQ Randomized, Double-blind, Placebo-controlled Trial, 4. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. POSTER: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 14. Hwee J, Smith S, Small M, et al. Get email updates for new Gsk Medical Affairs jobs in United States. 811; Abstract A4300]. Lan Y, Zhang D, Xu C, et al. 21. Faes S, Dormond O. PI3K and AKT: unfaithful partners in cancer. Assessment of Asthma Control in Respiratory Specialist Offices in the US. The antibody component of belantamab mafodotin enhances antibody-dependent cellular cytotoxicity and phagocytosis (ADCC/ADCP). An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. A prospective evaluation of tolerability of niraparib dosing based upon baseline body weight and platelet count: blinded pooled interim safety data from the PRIMA/ENGOT-OV26/GOGO3012 Study, 6. POSTER: Efficacy of dostarlimab in endometrial cancer (EC) by molecular subtype: A post hoc analysis of the GARNET study, 6. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Treatment Patterns and Disease Burden of Triple Therapy in Asthma. Nathan R, Boulet L-P, Kerstjens HA, et al. , Have you heard of #myelofibrosis, a rare form of blood cancer? Wu AC, McMahon PM, Mendelsohn A, et al. 5. Encore: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) Cytogenetics [Poster not available for viewing due to copyright restrictions], 8. 5. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis, 3. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge. Kovalszki A, Wechsler M, Silver J, et al. Baseline Platelet Count and Body Weight as Predictors of Early Dose Modification in the QUADRA Trial of Niraparib Monotherapy for the Treatment of Heavily Pretreated (?4th Line), Advanced, Recurrent High Grade Serous Ovarian Cancer, 4. Efficacy of Umeclidinium/Vilanterol Versus Umeclidinium or Salmeterol: A Number-Needed-to-Treat Analysis of the EMAX Trial. Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by ACQ and SGRQ Quartiles. Activation of inducible T-cell costimulator (ICOS) supports proliferation and functional activity of effector T cells and expands memory T-cell populations, which promote durable anti-tumor responses. You can unsubscribe from these emails at any time. Ismaila A, Haeussler K, Czira A, et al. and Physicians? Nonclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. and Physicians? 1. Working closely with our employee resource groups, we launched the Accelerating Difference - Ethnic Diversity development program. Phase 2, Multi Arm Study of Niraparib in Combination With a PD 1 Inhibitor in Patients With Non Small Cell Lung Cancer: JASPER, Bintrafusp Alfa Bifunctional TGF-? Zhang S, Czira A, Harley J, et al. NY-ESO-1?specific TCR?engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Neutrophil extracellular traps and CXCR2 antagonism in chronic obstructive pulmonary disease: A pilot randomized control study. Search job openings, see if they fit - company salaries, reviews, and more posted by GSK employees. POSTER: Impact of Initiation Timing of Niraparib Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer, 6. The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against HZ: Interim Results of an Extension Study of Two Clinical Trials, 7. Real-World Effectiveness Of Mepolizumab In Patients With Allergic And Non-Allergic Asthma. Healthcare Resource Utilization and Costs Over 5 Years for a Systemic Lupus Erythematosus Cohort Newly Diagnosed With Lupus Nephritis: Evidence From a US Administrative Claims Database. 2. Plain Language Summary [HCP USE ONLY]: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 4. Mar 2022 - Present1 year 2 months. 7. POSTER: Evaluation of an Individualized Starting Dose of Niraparib in the PRIMA/ENGOT-OV26/GOG-3012 Study, 4. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study, 1. Ajude-nos a manter o Glassdoor seguro confirmando que voc uma pessoa de Bogart M, Bunner S, Johnson MG, et al. Improvements in COPD Symptoms With Umeclidinium/Vilanterol Analyzed by Baseline CAT Score: A Post Hoc Analysis of the EMAX Trial. POSTER: Real-World Trends of PARPi Maintenance Treatment Uptake and Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Advanced Ovarian Cancer (AOC) in the US, 8. Chandler R et al. 373. Evaluation of immune phenotypes and gene expression profiles in tumors from patients treated with bintrafusp alfa, 4. Apply to Public Health Nurse, Medical Director, Senior Director and more! Tim-3 and its role in regulating anti-tumor immunity. Poster No. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. 4. Steinfeld J, Roufosse F, Kahn JE, et al. DREAMM-6: Safety, Tolerability, and Clinical Activity of Belantamab Mafodotin (Belamaf) in Combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM), 8. Niraparib is being investigated as a monotherapy and in combination with other anticancer agents, including dostarlimab, in breast cancer, ovarian cancer, and advanced NSCLC. 3. POSTER: Evaluation of cCRESS in Phase 2 Randomised Placebo-controlled Study of Sequential Belimumab/Rituximab Administration in Patients with Primary Sjogren's Syndrome, 3. Kickstart your career at GSK by applying to any one of our Early Talent Programmes programmes. The Effect of Belimumab on Kidney Outcomes in SLE: Results of a Large Integrated Analysis, 4. Hemoglobin Efficacy and Cardiovascular Safety Data from the ASCEND-ND, -D, and -ID Trials. Leverage your professional network, and get hired. The focus you find throughout GSK will help you take ownership of your career and build and contribute to high-performing teams. Real-World Impact of Triple Therapy with Fluticasone Furoate, Umeclidinium, and Vilanterol on Asthma Control among Patients with Asthma in the US. Montes de Oca R, Bhattacharya S, Vitali N, et al. P1488. Real-World Impact of Systemic Corticosteroid (SCS) Exposure on Healthcare Resource Utilization (HRU) due to SCS-Related Complication among Patients with Asthma in the US? Expression of myeloma cell BCMA and soluble BCMA in relapsed and refractory multiple myeloma subjects treated with GSK2857916 in BMA117159, 4. 3888792. Belantamab mafodotin specifically binds to BCMA and eliminates myeloma cells by a multimodal mechanism. Gsk Medical Jobs in London | Indeed.com Upload your CV and easily apply to jobs from any device! Dostarlimab is a humanized anti?PD-1 mAb that binds with high affinity to PD-1 and effectively blocks interactions with PD-L1 and PD-L2. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that interacts with the PD-1 ligands PD-L1 and PD-L2 to limit T-cell?mediated immune responses. POSTER: Utility of circulating tumor DNA in breast cancer clinical research and practice: systematic review and meta-analysis, 2. 3. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-. [Poster No. A phase I study of GSK525762, a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of phase I/II open label single agent study in patients with acute myeloid leukemia (AML). POSTER: Single-agent Belantamab Mafodotin in Patients With Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 trial, 2. Patient-Reported Experience of Eosinophil-Driven Diseases on Online Platforms: Social Listening Analysis Insights. B-cell maturation antigen (BCMA), a membrane protein expressed on malignant plasma cells in all patients with multiple myeloma, supports myeloma cell proliferation and survival. Trade marks are owned by or licensed to the GSK group of companies. Strobel M, Alves D, Roufosse F, et al. Schwarz TF et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Impact of umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO), fluticasone propionate/salmeterol (FP/SAL), and budesonide/formoterol (B/F) on time-to-first severe exacerbation among patients with chronic obstructive pulmonary disease with high comorbidities and high costs. Information Database, Vaccine Temperature Aydanos a proteger Glassdoor verificando que eres una persona real. Bell CF, et al. We bring together the best and brightest minds to be ambitious for our patients. GSK is committed to the discovery and development of new vaccines and oncology and hematology compounds that leverage patient-driven science to deliver improved outcomes for more patients. ORAL PRESENTATION: Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor, 3. Bring your unwanted, unused, and expired medicines to the 24th@DEAHQQ's National Prescription Drug#TakeBackDayy between 10AM - 2PM. Cole AL, Moretz C, Mu G, et al. ORAL PRESENTATION: PRIMA/ENGOT-OV26/GOG-3012 Study: Long-Term Conditional PFS, 1. 1. Safety and reactogenicity of RZV: Experience from clinical trials and post-marketing. . Analysis of Co-Resistance Among Escherichia coli Urine Isolates From Female Outpatients in the United States. PUBLICATION ONLY: Standards of Care and Treatment Patterns Among Relapsed/Refractory Multiple Myeloma Patients Initiating Second- and Third-Line Therapies, 15. POSTER: A first-in-clinic phase 1 study of GSK3745417 STING agonist in relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, 1. Singh AK, et al. 336), 1. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448) Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Keeley T, et al. P699; Abstract A1814]. If not, try adjusting your search terms or contact GSK Medical Information at 1-877-GSK-MI4U (1-877-475-6448). Careers Ahead Together Here at GSK, we unite science, technology and talent to get ahead of disease together. 1. P806; Abstract A4295]. Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom. Insights From Allergy Practice. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Obrador GT, et al. Epidemiology of Lupus Nephritis in Brazil: Findings From the Macunama Study ? 2. . Trade marks are owned by or licensed to the GSK group of companies. DREAMM-4: Evaluating Safety and Clinical Activity of Belantamab Mafodotin in Combination With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 14. P1501. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. What we do can transform our patient and shareholder outcomes, and the experience of our people. Dawson M, Stein EM, Huntly BJP, et al. Bintrafusp alfa is a bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor ? Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-? Real-World Benefits of Mepolizumab in Patients with Severe Asthma and Comorbid Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Post Hoc Analysis of REALITI-A. We are committed to doing the right thing: our ambition is to improve the lives of billions across the world. Moraes F, Abreu G, Nogueira T, et al. 805; Abstract A4294]. Singer D et al. Real-World Benefits of Mepolizumab in Patients With Overlapping Allergic and Eosinophilic Endophenotypes: Post Hoc Analysis of REALITI-A by Omalizumab Eligibility (Poster No. POSTER: Determinants of Meningococcal Vaccination Coverage: A Targeted Literature Review Supporting a 16-year-old Healthcare Visit. Bogart M, Bengtson L, Rothnie K, et al. ", Explore our career opportunities all over the world, We strive to attract the best people and create an environment that, Every world-class scientist or inspiring leader had to start somewhere, We value what you bring and believe you can successfully transfer it to a, As we age, the #immunesystem weakens making us more vulnerable to #infectiousdiseases. Singh AK, et al. Resistance analysis in the COMET-ICE study: sotrovimab treatment in participants with mild-to-moderate COVID-19. Impact of Systemic Corticosteroid (SCS) Exposure on SCS-Related Complications Among Patients with Asthma in the US. Patients? Further details on cookies and how to object to their placement can be found in our Cookie Policy. perspective on the burden of Hypereosinophilic Syndrome. 5. Luong A, Levy J, Klimek L, et al. 3. (Poster No. We are committed to doing the right thing: our ambition is to improve the lives of billions across the world. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. ?Trap?/Anti-PD-L1 Fusion Protein, Belantamab Mafodotin - Anti-BCMA Immunoconjugate, PRMT5 Inhibitor (GSK3326595) and Type I PRMT Inhibitor (GSK3368715). [Poster No. 1. Maximal Change in Erythropoietin in Hemodialysis ?Patients Receiving Daprodustat or Epoetin Alfa ?in the ASCEND-TD Trial, 9. If you require an accommodation or other assistance to apply for a job at GSK, please contact the GSK Service Centre at 1-877-694-7547 (US Toll Free) or +1 801 567 5155 (outside US). and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC), 14. Changes in Oral Corticosteroid (OCS) Use Following Initiation of Mepolizumab Therapy in Patients with Asthma. 2018;22(4):343-351. LAG3 (CD223) as a cancer immunotherapy target. P1286; Abstract A6579]. POSTER: Exploring Alternative Dosing Regimens of Single-agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14, 6. Aydanos a proteger Glassdoor y demustranos que eres una persona real. Poster No. ABSTRACT ONLY: Biomarker correlates of letetresgene autoleucel (lete-cel; GSK3377794) response in patients with advanced myxoid/round cell liposarcoma (MRCLS), 2. 714; Abstract A4267]. Busse W, Chupp G, Stanaland M, et al. 115 Medical Affairs Gsk jobs available on Indeed.com. Johansen K, et al. Single-agent Belantamab Mafodotin for RRMM: Analysis of the Lyophilized Presentation Cohort from the Pivotal DREAMM-2 Study [Poster not available for viewing due to copyright restrictions], 9. POSTER: Master protocol to assess the safety and recommended phase 2 dose of next generation NY-ESO-1?specific TCR T-cells in HLA-A*02 patients with synovial sarcoma and non-small cell lung cancer, 1. 2. Ramesh N, Hegewald M, Maselli DJ, et al. Strong industry experience, spanning clinical development and medical affairs. PUBLICATION ONLY: DREAMM-2: Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin Versus Selinexor Plus Dexamethasone Combination in Anti-CD38 Exposed Relapsed/Refractory Multiple Myeloma, 26. Real World Evidence in Asthma: Pulmonary Function and Asthma Control in Respiratory Specialty Clinics in the US. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. Erythropoiesis-Stimulating Agent Hyporesponsiveness and Anemia Management in the ASCEND-D Trial? PLAIN LANGUAGE SUMMARY [HCP USE ONLY]: ENGOT-EN6/GOG-3031/ NSGO-RUBY: A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab + Carboplatin? Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation. POSTER: Ovarian Cancer Retrospective European (O?CaRE) Observational Study: Analysis of First-Line (1L) Outcomes in Patients With Ovarian Cancer (OC) Stratified by Number of Risk Factors for Progression, 7.

Andy Scott Four In A Bed, Que Piensa Un Hombre Mujeriego De Una Mujer Virgen, Articles G